छोड़कर सामग्री पर जाएँ

Latest News

Revlimid overdose boosts Dr Reddy#39;s Q3 earnings, but turns brokerages cautious

Revlimid overdose boosts Dr Reddy#39;s Q3 earnings, but turns brokerages cautious

While Dr Reddy#39;s recorded its highest-ever quarterly revenue in Q3, most of the growth was fueled by a higher-than-expected contribution from cancer drug Revlimid while the base US and India business delivered a subpar performance. Read More ​ While Dr Reddy#39;s… और पढ़ें »Revlimid overdose boosts Dr Reddy#39;s Q3 earnings, but turns brokerages cautious

hi_INहिन्दी